

AHPWA22AUSA

REMARKS/ARGUMENTS

After entry of this paper, claims 1-17 and 20-27 are pending. New claims 26-27 are supported on page 21, lines 3-6. No new matter is added by these new claims.

35 USC § 112, First Paragraph Rejection

Claims 1-18 and 20-25 are rejected under 35 USC § 112, first paragraph.

The Examiner asserted that (i) there is insufficient descriptive support for the phrases metabolites and prodrugs; (ii) that the instant specification does not describe what is meant by the phrases metabolites and prodrugs; and (iii) that there is no evidence that there is any per se structure/function relationship between the phrases "metabolites and prodrugs".

Applicants respectfully request reconsideration and withdrawal of this rejection for the following reason.

The originally filed specification more than supports embodiments whereby the compounds of the invention are useful in the claimed methods as their metabolites and prodrugs thereof. See, e.g., page 6, line 22; page 7, lines 6-7 and 22; page 8, line 9; page 9, line 18; page 11, line 5; page 12, line 16; page 14, line 2; page 16, lines 25 and 28; page 21, lines 3-6; and in the original claims. Further, since these terms were readily understood by one of skill in the art as of the priority date of this application and are readily understood at the present time, definitions for "metabolite" and "prodrug" were not and need not be provided in the instant specification. In fact, Applicants note that when searches are performed on the Internet in an effort to obtain definitions for the terms "metabolite" and "prodrug", a large number of results are obtained, thereby demonstrating that these terms are well known in the art.

It is well known in the art as of the priority date of this application that the term "pro-drug" includes a chemical compound that converts to another compound *in vivo*. The term "metabolite" includes chemical compounds that are produced when other chemical compounds are subject to metabolic processes of the body.

AHPWA22AUSA

In view thereof, Applicants respectfully assert that the terms "metabolites" and "prodrugs" are adequately described by the specification, thereby satisfying the written description requirement for these terms.

Reconsideration of this rejection is requested.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON

By Cathy A. Kodroff
Cathy A. Kodroff
Registration No. 33,980
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818